Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 52, 2023 - Issue 5
Submit an article Journal homepage
1,742
Views
2
CrossRef citations to date
0
Altmetric
Articles/Brief Reports

Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland

I Koskivirta1 Centre for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland;2 Department of Medicine, University of Turku, Turku, FinlandView further author information
,
J Ruotsalainen3 Real-world Evidence and Research Services, Oriola Finland Ltd, Espoo, FinlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1056-3838View further author information
ORCID Icon,
S Kurki3 Real-world Evidence and Research Services, Oriola Finland Ltd, Espoo, FinlandORCID Iconhttps://orcid.org/0000-0002-6102-0369View further author information
ORCID Icon,
P Lakkakorpi4 Medical Department, Amgen AB, Espoo, FinlandORCID Iconhttps://orcid.org/0000-0001-9429-6495View further author information
ORCID Icon,
H Salminen-Mankonen3 Real-world Evidence and Research Services, Oriola Finland Ltd, Espoo, FinlandView further author information
,
L Pirilä1 Centre for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland;2 Department of Medicine, University of Turku, Turku, FinlandORCID Iconhttps://orcid.org/0000-0002-4276-7344View further author information
ORCID Icon,
R Harvima5 Departments of Dermatology, University of Eastern Finland and Kuopio University Hospital, Kuopio, FinlandORCID Iconhttps://orcid.org/0000-0002-0076-9093View further author information
ORCID Icon &
A Palomäki1 Centre for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland;2 Department of Medicine, University of Turku, Turku, FinlandORCID Iconhttps://orcid.org/0000-0002-8835-8116View further author information
ORCID Icon show all
Pages 549-555 | Received 02 Mar 2022, Accepted 21 Nov 2022, Published online: 16 Jan 2023

References

  • Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017;376:957–70.
  • Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021;397:1301–15.
  • Juneblad K, Kastbom A, Johansson L, Rantapää-Dahlqvist S, Söderkvist P, Alenius GM. Association between inflammasome-related polymorphisms and psoriatic arthritis. Scand J Rheumatol 2021;50:206–12.
  • Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, et al. Biologic treatments of psoriasis: an update for the clinician. Biol Targets Ther 2021;15:39–51.
  • Carrascosa JM, Del-Alcazar E. Apremilast for psoriasis treatment. G Ital Dermatol Venereol 2020;155:421–33.
  • Social Insurance Institution of Finland. 377 Apremilasti ja dimetyylifumaraatti (psoriaasi) - kela.fi [Internet]. [ cited 2022 Apr 20]. Available from: https://www.kela.fi/laake377
  • Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019;155:1142–52.
  • Sawyer LM, Cornic L, Lå L, Gibbons C, Møller AH, Jemec GB. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol 2019;33:355–66.
  • Kawalec P, Holko P, Moćko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int 2018;38:189–201.
  • Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2018;32:1173–9.
  • Abignano G, Fadl N, Merashli M, Wenham C, Freeston J, McGonagle D, et al. Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience. Rheumatology (Oxford) 2018;57:578–80.
  • Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, et al. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol 2020;34:2821–9.
  • Kishimoto M, Komine M, Kamiya K, Sugai J, Ohtsuki M. Drug survival of apremilast in a real-world setting. J Dermatol 2019;46:615–7.
  • Sbidian E, Billionnet C, Weill A, Maura G, Mezzarobba M. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database. Br J Dermatol 2020;182:690–7.
  • Augustin M, Kleyn CE, Conrad C, Sator PG, Ståhle M, Eyerich K, et al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatology Venereol 2021;35:123–34.
  • Psoriasis and psoriatic arthritis. Current care guidelines. Working group set up by the Finnish Medical Society Duodecim, Finnish Dermatological Society and Finnish Society for Rheumatology. Helsinki: The Finnish Medical Society Duodecim, [ cited 2022 Apr 20]. Available from: www.kaypahoito.fi
  • Haverinen S, Vihervaara A, Loyttyniemi E, Peltonen S, Koulu L, Tasanen K, et al. Validation of psoriasis diagnoses recorded in Finnish biobanks. Acta Derm Venereol 2020 Oct 7;100:adv00297. Epub ahead of print.
  • Gasparini A. comorbidity: an R package for computing comorbidity scores. J Open Source Softw 2018;3:648.
  • Feldman SR, Zhang J, Martinez DJ, Lopez-Gonzalez L, Marchlewicz EH, Shrady G, et al. Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis. Dermatol Online J 2021;27:1–9.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.